Showing 2221-2230 of 4063 results for "".
- Duke Eye Center Implants Cell-Based Therapy for MacTelhttps://modernod.com/news/duke-eye-center-implants-cell-based-therapy-for-mactel/2484304/Duke Eye Center announced that its team is the first at a US academic medical center to implant a new commercially available cell-based gene therapy for macular telangiectasia type 2 (MacTel). No treatment was available to slow the progression of MacTel until the FDA approved revakinagene taroret
- Viridian Submits BLA for Veligrotug in Thyroid Eye Diseasehttps://modernod.com/news/viridian-submits-bla-for-veligrotug-in-thyroid-eye-disease/2484303/Viridian Therapeutics has submitted a Biologics License Application (BLA) to the FDA for veligrotug, the company’s investigational therapy for thyroid eye disease (TED). The submission, completed in October, follows positive results from two pivotal phase 3 trials, THRIVE and THRIVE-2, that
- Novartis Announces Positive Phase 3 Results for Ianalumab in Sjögren’s Diseasehttps://modernod.com/news/novartis-announces-positive-phase-3-results-for-ianalumab-in-sjogrens-disease/2484297/Novartis announced new late-breaking data from the NEPTUNUS-1 and NEPTUNUS-2 phase 3 trials evaluating ianalumab in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease. The results, presented during the American College of Rheumatol
- OneSight EssilorLuxottica Foundation and Vision To Learn Extend Partnership to Expand Vision Care for Children Nationwidehttps://modernod.com/news/onesight-essilorluxottica-foundation-and-vision-to-learn-extend-partnership-to-expand-vision-care-for-children-nationwide/2484209/The OneSight EssilorLuxottica Foundation and Vision To Learn announced a 2-year extension of their 8-year partnership dedicated to providing vision care services to children in need—helping them see clearly and reach their full potential in school and be
- FDA Clears Complement Therapeutics’ IND Application for CTx001 Gene Therapy in GAhttps://modernod.com/news/fda-clears-complement-therapeutics-ind-application-for-ctx001-gene-therapy-in-ga/2484178/Complement Therapeutics has announced that the FDA has cleared its investigational new drug (IND) application for CTx001, the company’s lead gene therapy candidate. The clearance paves the way for the initiation of Opti-GAIN, a phase 1/2 clinic
- AAVantgarde Bio Presents Clinical Data from LUCE-1 Gene Therapy Trial in Usher Syndrome Type 1Bhttps://modernod.com/news/aavantgarde-bio-presents-clinical-data-from-luce-1-gene-therapy-trial-in-usher-syndrome-type-1b/2484135/AAVantgarde Bio announced updated clinical results from its ongoing LUCE-1 phase 1/2 study of AAVB-081, presented at the 25th European Society of Retina Specialists (EURETINA) annual congress in Paris. The LUCE-1 study
- FDA Clears IND for Opus Genetics’ OPGx-BEST1 Gene Therapy Candidatehttps://modernod.com/news/fda-clears-ind-for-opus-genetics-opgx-best1-gene-therapy-candidate/2484123/Opus Genetics announced that the FDA has accepted its investigational new drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal diseases (IRDs). The company now plans to initiate a Phase 1/2 clinical trial in the second
- Opus Genetics Phase 3 Trial for Phentolamine Ophthalmic Solution Meets Primary Endpoint for Night Visionhttps://modernod.com/news/opus-genetics-phase-3-trial-for-phentolamine-ophthalmic-solution-meets-primary-endpoint-for-night-vision/2482828/Opus Genetics announced positive topline results from LYNX-2, a phase 3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Patients who undergo kera
- Atsena Therapeutics Announces Positive Clinical Data for Gene Therapy to Treat X-linked Retinoschisis (XLRS)https://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-for-gene-therapy-to-treat-x-linked-retinoschisis-xlrs/2482808/Atsena Therapeutics announced interim data from Part A of its phase 1/2 LIGHTHOUSE clinical trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The study demonstrated a favorable safety profile and compelling signs of efficacy in adul
- Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVOhttps://modernod.com/news/opus-genetics-announces-presentation-of-opgx-lca5-gene-therapy-data-at-arvo/2482782/Opus Genetics announced 1-year results from adult patients treated in the ongoing phase 1/2 Study of its lead gene therapy candidate OPGx-LCA5. These results were presented at the 2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), taking place May 4